Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Posters/Exhibits/Break > Session
Posters/Exhibits/Break
Presentations
A4. DISORDERS OF PLATELET NUMBER OR FUNCTION | |||||
|
(501) PLATELET DYSFUNCTION IN PEDIATRIC PATIENTS ON THE KETOGENIC DIET Kristin N. Maher1, Susanna Fenstermacher2, Nabiha H. Saifee3, Jason P. Lockrow4. 1Department of Pediatrics, Division of Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy, University of Washington, Seattle, WA, USA 2Division of Pediatric Neurology, Seattle Children's Hospital, Seattle, WA, USA 3Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA 4Department of Neurology, University of Washington, Seattle, WA, USA |
||||
A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS | |||||
|
(503) LABORATORY VALIDATION OF TECHNOFLUOR FXIII ACTIVITY ON CEVERON S100 INSTRUMENT Rachel R Leger, Juliana Perez Botero, M.D., Dong Chen, M.D., Ph.D., Rajiv K Pruthi, M.B.B.S. Mayo Clinic, Rochester, MN, USA |
||||
|
(504) HEAT INACTIVATION OF EFANESOCTOCOG ALFA (ALTUVIIIO) IN PATIENT'S PLASMA TO ACCURATELY DETERMINE FACTOR VIII INHIBITOR TITER BY BETHESDA ASSAY. Andrea Staum, Andrew Podd, Tina Agostini, Geoffrey Wool, Bailey Hutchison, Sandra Haberichter, Kenneth Friedman. Versiti, Milwaukee, WI, USA |
||||
A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS | |||||
|
(505) TRANSAMINASE ELEVATIONS IN THE FITUSIRAN CLINICAL DEVELOPMENT PROGRAM WITH THE ANTITHROMBIN-BASED DOSE REGIMEN Sanjay Ahuja1, Savita Rangarajan2,3, Chur-Woo You4, Bulent Zulfikar5, Abhimanyu Yarramaneni6, Laurel A Menapace6, Yuqian Shen6, Steven W Pipe7. 1Rainbow Hemostasis & Thrombosis Center, University Hospitals Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA 2Advanced Centre for Oncology, Haematology and Rare Diseases, K.J. Somaiya Super Specialty Hospital, Mumbai, India 3Faculty of Medicine, University of Southampton, Southampton, United Kingdom 4Department of Pediatrics, Eulji University School of Medicine, Daejeon, South Korea 5Division of Pediatric Hematology-Oncology, Istanbul University Oncology Institute, Istanbul, Turkey 6Sanofi, Cambridge, MA, USA 7Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA |
||||
|
(506) UNDERSTANDING INFORMATION ACCESS, TREATMENT DECISION-MAKING AND TREATMENT SATISFACTION AMONG CAREGIVERS OF CHILDREN WITH ≤17 YEARS OLD WITH HEMOPHILIA A OR B: PRELIMINARY FINDINGS FROM A SURVEY STUDY Poojita Dasika1, Jennifer Davila2. 1Albert Einstein College of Medicine, Bronx, NY, USA 2Albert Einstein College of Medicine, Department of Pediatrics, Bronx, NY, USA |
||||
|
(507) FROM EFFICACY TO EXPERIENCE: 52-WEEK PATIENT-REPORTED OUTCOMES WITH MIM8 IN ADOLESCENTS AND ADULTS WITH HEMOPHILIA A WITH OR WITHOUT INHIBITORS (FRONTIER2) Cédric Hermans1, Sanjay Ahuja2, Hazza Alzahrani3, Cihan Ay4, Peter Kampmann5, Samya Obaji6, Sophie Susen7, Ciprian Ionut Tomuleasa8, Lize van Vulpen9, Amalie Rhode Høgh Nielsen10, Ilgiz Rakhmatullin10, Emily Waters11, Carmen Escuriola-Ettingshausen12, Arjun Menon11. 1Division of Hematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium 2Department of Pediatric Hematology and Oncology, Rainbow Babies and Children’s Hospital, Cleveland, OH, USA 3Department of Hematology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia 4Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria 5Department of Hematology, Rigshospitalet, Copenhagen, Denmark 6Department of Haematology, Cardiff and Vale University Health Board, Cardiff, United Kingdom 7Hemostasis and Transfusion Department, University of Lille, Lille University Hospital, Lille, France 8Department of Hematology, “Ion Chiricuta” Institute of Oncology, Cluj-Napoca, Rumania 9Center for Benign Haematology, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands 10Novo Nordisk A/S, Søborg, Denmark 11Novo Nordisk, Inc., Plainsboro, NJ, USA 12Haemophilia Centre Rhein Main (HZRM), Frankfurt, Germany |
||||
|
(508) PRECISION AND REPRODUCIBILITY OF A NEW AUTOMATED CHEMILUMINESCENT IMMUNOASSAY FOR THE DETECTION OF ANTI-PLATELET FACTOR 4/HEPARIN (PF4/H) IGG ANTIBODIES Niki Leonard, Kerrie Jaskal. Werfen, Bedford, MA, USA |
||||
|
(509) BLEED TREATMENT OUTCOMES FROM THE XTEND-ED STUDY IN PATIENTS AGED 50 YEARS AND OLDER Johannes Oldenburg1, Barbara Konkle2, Toshko Lissitchkov3, Pratima Chowdary4, Liane Khoo5, Katsuyuki Futatake6, Elena Santagostino7, Helena Palmborg8, Linda Bystrická7, Jennifer Dumont9, Meredith Foster9, Sriya Gunawardena10, Andrew Wilson10, Annette von Drygalski11, Scott Cleland10. 1University Hospital Bonn, Bonn, Germany 2Washington Center for Bleeding Disorders, University of Washington, Washington, WA, USA 3Specialized Hospital for Active Treatment of Hematological Diseases, Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Sofia, Bulgaria 4Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom 5Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, Australia 6Ogikubo Hospital, Tokyo, Japan 7Sobi, Basel, Switzerland 8Sobi, Stockholm, Sweden 9Sanofi, Cambridge, MA, USA 10Sanofi, Morristown, NJ, USA 11Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, CA, USA |
||||
|
(510) TREATMENT OF ACQUIRED VON WILLEBRAND'S SYNDROME IN THE SETTING OF MONOCLONAL DYSPROTEINEMIAS Fatima Shaba, Serena Navitskas, Erin Aakre, Amanda Hertel, Dong Chen, Rajiv Pruthi, Meera Sridharan. Mayo Clinic, Rochester, MN, USA |
||||
|
(511) LABORATORY VALIDATION OF ADAMTS-13 ANTIBODY ASSAY Melissa S. Stuart, Rajiv K. Pruthi, M.B.B.S, Dong Chen, M.D., Ph.D.. Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA |
||||
|
(512) OVERVIEW ON MANAGEMENT OF BREAKTHROUGH BLEEDS AND MAJOR SURGERIES FOLLOWING BLEED MANAGEMENT GUIDELINES DURING THE FITUSIRAN CLINICAL PROGRAM IN PEOPLE WITH HEMOPHILIA Julian Zorrilla1, Kaan Kavakli2, László Nemes3, Tienan Zhu4, Stephanie P'ng5, Steven W Pipe6, Marek Demissie7, Abhimanyu Yarramaneni8, Yuqian Shen7, Umer Khan7, Guy Young9. 1Nemours Children’s Health, Division of Pediatric Hematology/Oncology, Jacksonville, FL, USA 2Division of Hematology, Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey 3National Haemophilia Center and Haemostasis Department, Center Hospital of Northern Pest - Military Hospital, Budapest, Hungary 4Peking Union Medical College Hospital, Beijing, China 5Fiona Stanley Hospital, Murdoch, Australia 6University of Michigan Medical Center, Department of Hemophilia and Coagulation Disorders, Ann Arbor, MI, USA 7Sanofi, Cambridge, MA, USA 8Sanofi, Morristown, NJ, USA 9Hemostasis and Thrombosis Center, Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA |
||||
A8. ANTITHROMBOTIC THERAPY | |||||
|
(514) EVALUATION OF COMPLIANCE WITH RECOMMENDATION TO TAKE RIVAROXABAN WITH FOOD Nghi Ha, Erin Mouland, Denise Sutter-Long, Elizabeth Renner, Anisa Bici. Michigan Medicine, Ann Arbor, MI, USA |
||||
|
(515) MECHANISTIC POPULATION PK/PD MODELLING OF REGN7508CAT SUPPORTS DOSE SELECTION FOR SUSTAINED FXI SUPPRESSION AND APTT RESPONSE IN HEALTHY VOLUNTEERS AND POST-SURGICAL VTE-PREVENTION PARTICIPANTS Oleg Milberg1, Hisham Abdallah1, Rachel Kudgus Lokken2, Robert Dingman1, Karoline A. Meagher1, Poulabi Banerjee1, Michael E. Burczynski1, Ethan Marin1, Aaron Kithcart1, David E. Gutstein1. 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA 2Allucent, Cary, NC, USA |
||||
A9. INFORMATIONAL ABSTRACT (POSTER ONLY) | |||||
|
(516) TRANSFORMING AF CARE: A LEARNING LAB APPROACH TO ADVANCING ANTICOAGULATION QUALITY IMPROVEMENT Geoffrey Barnes1, Tracy Blithe2, Amanda Katz3, Elizabeth Goldstein3, Julie Gouveia-Pisano4, Charles J Medico4, Barbara K Pritchard4, Julie Simonson4, Anne Marie Smith2. 1University of Michigan Medical School, Ann Arbor, MI, USA 2Heart Rhythm Society, Washington, DC, USA 3Anticoagulation Forum, Newton, MA, USA 4Pfizer Inc., New York, NY, USA |
||||
|
(517) CHARACTERIZING LOW MOLECULAR WEIGHT HEPARIN-ASSOCIATED BLEEDING RISK IN THROMBOLYSIS OR THROMBECTOMY FOR VENOUS THROMBOEMBOLISM Natasha Jolakoski, Lisa Koselke, Allison Burnett. University of New Mexico Hopsital, Albuqerque, NM, USA |
||||
|
(518) DISPARITIES IN ANTICOAGULATION PRESCRIBING ACROSS DIFFERENT RACE/ETHNICITIES Annjay Tabbilos, Joe Mazur, Sienna Miller, Jennifer Mazur, Julie Ann Ehret, Joli Fermo, Agnes Musyoka, Emily Overly. Medical University of South Carolina, Charleston, SC, USA |
||||